Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.

Autor: Avgerinos KI; 251 Hellenic Airforce General Hospital, Kanellopoulou 3, 11525, Athens, Greece. kwstas-avge@hotmail.com.; Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. kwstas-avge@hotmail.com.; Society of Junior Doctors, Athens, Greece. kwstas-avge@hotmail.com., Kalaitzidis G; Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.; Society of Junior Doctors, Athens, Greece., Malli A; Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.; Society of Junior Doctors, Athens, Greece., Kalaitzoglou D; Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.; Society of Junior Doctors, Athens, Greece., Myserlis PG; 401 General Army Hospital, Athens, Greece.; Society of Junior Doctors, Athens, Greece., Lioutas VA; Department of Neurology, Division of Cerebrovascular Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
Jazyk: angličtina
Zdroj: Journal of neurology [J Neurol] 2018 Jul; Vol. 265 (7), pp. 1497-1510. Date of Electronic Publication: 2018 Feb 01.
DOI: 10.1007/s00415-018-8768-0
Abstrakt: Background and Aims: Due to common pathophysiological findings of Alzheimer's disease (AD) with diabetes mellitus (DM), insulin has been suggested as a possible treatment of AD or mild cognitive impairment (MCI). A safe alternative of IV insulin is intranasal (IN) insulin. The aim of this systematic review is to investigate the effects of IN insulin on cognitive function of patients with either AD or MCI.
Methods: A literature search of the electronic databases Medline, Scopus and CENTRAL was performed to identify RCTs investigating the effect of IN insulin administration on cognitive tasks, in patients with AD or MCI.
Results: Seven studies (293 patients) met our inclusion criteria. Most studies showed that verbal memory and especially story recall was improved after IN insulin administration. Sometimes the effect was restricted for apoe4 (-) patients. Intranasal insulin did not affect other cognitive functions. However, there were some positive results in functional status and daily activity. Data suggested that different insulin types and doses may have different effects on different apoe4 groups. In addition, the effects of treatment on Αβ levels differed from study to study. Finally, IN insulin resulted in minor adverse effects.
Conclusions: Intranasal insulin improved story recall performance of apoe4 (-) patients with AD or MCI. Other cognitive functions were not affected, but there were some positive results in functional status and daily activity. Since IN insulin is a safe intervention, future studies should be conducted with larger doses and after proper selection of patients and insulin types.
Databáze: MEDLINE
Externí odkaz: